France
Mitologics is a pioneering biotechnology company founded in 2009 and headquartered in the Paris area of France. The company specializes in the detection of mitochondrial injury, a critical factor in regulating cell death. Focusing on both toxicity and efficacy, Mitologics offers screening services that utilize predictive assays on isolated healthy and pathological mitochondrial and cellular models.
The company has developed three proprietary screening platforms: MiToxView® for predictive toxicity assays, MitoPathway® for efficacy assays on tumor mitochondria, and MitoXpert® for mitochondrial targeting and protection. These assays, particularly those on isolated mitochondria from mouse liver and human hepatocytes, are known for their high predictivity of hepatotoxicity in humans, as validated by researchers like Porceddu et al., 2012.
Their last known investment event was a Venture Round in which they received backing from AGORANOV on 01 March 2009. As Mitologics continues to make strides in biotechnology, their sophisticated assay technologies offer promising avenues for addressing cellular health challenges.
